Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.60 |
| ▸ | TOP1 | P11387 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280663 | 0.86 | SYK (0.71) | SYKAURKANPC1RAB9AKDM4E | |
| SCHEMBL11370448 | 0.84 | SYK (0.76) | SYKTOP1DYRK1ACLK4CYP19A1 | |
| SCHEMBL524226 | 0.82 | SYK (0.55) | SYK | |
| SCHEMBL4769223 | 0.81 | CYP1A2 (0.48) | TOP1DYRK1ACLK4ABCG2RAB9A | |
| SCHEMBL3280921 | 0.80 | CDC7 (0.48) | SYKCYP19A1CCNB2CDK1CCNB1 | |
| SCHEMBL523765 | 0.79 | SYK (0.64) | SYK | |
| SCHEMBL524455 | 0.78 | SYK (0.53) | SYKCYP19A1NPC1RAB9A | |
| SCHEMBL523222 | 0.76 | SYK (0.58) | SYKABCG2GSK3B | |
| SCHEMBL22201437 | 0.76 | PRKCH (0.56) | SYKNPC1KDM4EMAPK1 | |
| SCHEMBL13406834 | 0.76 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705151-B2 | 1,6 Naphthridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678911-B2 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | CYWIN CHARLES L | 2008-05-15 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321041-B2 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057695-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229090-A1 | 1,6 Naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | SYK 1/4885TOP1 2415/4885DYRK1A 809/4885 |
| US-20080114024-A1 | 1,6 NAPHTHYRIDINES USEFUL AS INHIBITORS OF SYK KINASE | SYK, IRAK1, IRAK3 | SYK 1/4885TOP1 2754/4885DYRK1A 784/4885 |
| US-20090171089-A1 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE | SYK, IRAK1, IRAK3 | SYK 1/4885TOP1 3129/4885DYRK1A 501/4885 |
| US-20030158195-A1 | 1,6 naphthyridines useful as inhibitors of SYK kinase | SYK, IRAK1, BTK | SYK 1/4885TOP1 2415/4885DYRK1A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.